Table 1.
Effects of (graft) treatments on hematopoietic stem cell transplantation
| Treatment | Removed | Remaining | Effect |
| Complete T cell depletion | All T cells | N/A | GvHD ↓[8,14,44] |
| Disease relapse ↑[8,9,44] | |||
| Graft failure ↑[8,9,44] | |||
| Immune reconstitution ↑[44] | |||
| Partial T cell depletion | CD45RA (TNV) | CD45RO (TMEM) | GvHD ↓[20,21,22] |
| CD62L+ (TNV, TCM)1 | CD62L- (TEM)1 | Neutrophil engraftment ↑[22] | |
| Immune reconstitution ↑[20] | |||
| Protective immunity ↑[21,22] | |||
| Donor chimerism ↑[20,22] | |||
| Donor lymphocyte infusion | CD45RA (TNV) | CD45RO (TMEM) | GvHD ↓[26] |
| CD62L+ (TNV, TCM)1 | CD62L- (TEM)1 | Tumor growth ↓[26] | |
| Engraftment ↑[26] | |||
| Graft failure ↓[26] | |||
| Immune reconstitution ↑[26] | |||
| Protective immunity ↑[26,28] | |||
| Donor chimerism ↑[26,27] |
1
Signifies the murine equivalent of the human T cell subset described above. Here, we summarize the impact that either full or partial T cell depletion of an HSPC graft, or selective donor lymphocyte infusion, can have on the clinical outcome of a HSPC transplantation. Indicated are the T cell subsets that have either been removed or that remain, and the biological or clinical effects that have been reported following this treatment. N/A: Not available; HSPC: Hematopoietic stem and progenitor cell; GvHD: Graft-vs-host disease.